Learn More About Ceftriaxone and ALS

by Margaret Wahl on Wed, 2010-09-01 14:14

Investigators on a study of ceftriaxone in amyotrophic lateral sclerosis (ALS) will host an informational webinar Tuesday,  Sept. 7, 2010

Login information for webinar changed 9/1/10

Article Highlights:
  • A trial of intravenous ceftriaxone in amyotrophic lateral sclerosis (ALS) is recruiting at 54 centers.
  • Details about the rationale for testing ceftriaxone in ALS and the study's procedures will be described in a webinar on Sept. 7, 2010, at 3 p.m. EDT.
  • Interested persons can attend from home and ask questions.

Editor's note: The information on joining this webinar has been updated, per the presenters, Sept. 1, 2010.

A clinical trial of the drug ceftriaxone in amyotrophic lateral sclerosis (ALS) is currently recruiting participants at 54 locations across the United States and Canada. (For details, see Ceftriaxone Trial Still Open.) Laboratory studies suggest the drug protects motor neurons from injury.

Neurologist Merit Cudkowicz, the study's principal investigator, will hold an informational webinar (web-based seminar) for people interesting in learning more about this clinical trial. The webinar will focus on the scientific rationale for ceftriaxone in ALS and the study procedures. Attendees can ask questions.

Join the seminar on Tuesday, Sept. 7, 2010, at 3 p.m. EDT by doing the following:

The presenters recommend going online to register for the webinar a day or two before the presentation. After registering, you will receive a confirmation e-mail containing information about joining the webinar.

The program will ask that you enter your first and last name upon registration. To protect your privacy, the presenters ask that you enter your initials only or your first name and last initial.

The Go-To-Webinar software is compatible with the following computer systems:
PC-based attendees - Windows® 7, Vista, XP or 2003 Server
Macintosh-based attendees - Mac OS® X 10.4.11 (Tiger®) or newer

No votes yet
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy